Adlore

About the offering

Adlore, Inc. is a pre-revenue medical device startup developing SenLore, a patented home-use system designed to treat diabetic foot ulcers (DFUs). The company was founded by Daryl Lawson, PT, MPT, DSc, a clinician and researcher with decades of experience treating DFUs across three universities. Adlore's core technology combines electrical stimulation and thermal therapy delivered via non-adhesive insole electrodes, using a proprietary 'whirlpool' stimulation pattern that the company claims increases blood perfusion by 3x compared to traditional two-electrode systems. Internal and university-led clinical research reportedly demonstrates healing rates of up to 70%, versus approximately 25% with standard care. The company targets the estimated $11–15 billion DFU treatment market, with a particular focus on underserved populations in rural communities and communities of color who face disproportionately higher amputation rates. Adlore's business model centers on high-margin hardware (manufactured for under $500) paired with recurring revenue from proprietary consumables and Remote Patient Monitoring (RPM) reimbursements via established CPT codes (99453, 99454, 99457). Target institutional customers include the VA, Kaiser, and the NHS. The company holds a multi-jurisdictional patent portfolio covering the US, Canada, and the EU, protecting the therapy, sensors, and therapeutic boots. As of the offering, Adlore is in the pre-commercialization phase with zero revenue, zero employees, and zero customers. It has $13,013 in cash, $106,053 in total assets, $749,500 in debt, and a monthly burn rate of $6,250, giving approximately two months of runway. A functional prototype of SenLore is targeted for completion by December 2026, with clinical trials and an FDA 510(k) submission planned for January 2027. The company has noted early interest from potential strategic acquirers. The team includes CEO Daryl Lawson, Engineering Advisor Chris Arena, PhD (Assistant Professor at Virginia Tech, Department of Biomedical Engineering), and CFO Matt Alessi (Managing Director of CFOx, with experience advising 40+ investor-backed startups). The Reg CF offering is being conducted through Highlander Crowdfunding, selling Common Stock at $0.84 per share with a minimum investment of $250.32, targeting between $9,999.36 and $1,000,000.68, with an offering deadline of June 30, 2026.

FAQ